☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Rallybio
Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT
October 30, 2024
Rallybio Partners with Johnson & Johnson on Therapeutic Solutions to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT...
April 11, 2024
Rallybio Presents P-I Single Ascending Dose Results of RLYB116 for Complement-Mediated Diseases at ICW 2023
September 4, 2023
Martin Mackay, CEO of Rallybio, Shares his Thoughts on the Appointment of Jonathan I. Lieber as Chief Financial Officer
April 10, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.